VIPER aims to fast track Long COVID biomarkers. Here’s how it works.
Led by researchers at UCSF, the research program plans to validate promising candidates for noninvasive tests that can be used to advance clinical trials. The post VIPER aims to fast track Long COVID biomarkers. Here’s how it works. first appeared on The Sick Times .
The University of California, San Francisco (UCSF) has launched a new program called VIPER (Viral Immunopathogenesis and Persistence Repeat Donor Cohort) to quickly identify potential biomarkers for Long COVID. This initiative, funded with a $1.35 million donation from the PolyBio Research Foundation, aims to accelerate the search for noninvasive tests that can be used in clinical trials.
VIPER will initially focus on biomarkers related to viral persistence, with a cohort of 150 participants, 100 experiencing Long COVID and 50 who had COVID-19 but recovered. If promising, these tests will be expedited for clinical trials and widespread use. Long COVID's diverse symptoms and complex presentations have made the search for biomarkers extremely challenging.
Historically, the rapid development of HIV diagnostic tests after its discovery in 1985 served as a model for quick advancements in medical diagnostics. However, Long COVID has lagged behind in this regard, with no reliable and useful biological tests yet identified.
Written by urgent.news from The Sick Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 2 other outlets
- 27% of UK health care workers report long COVID symptoms medicalxpress.com
- Long Covid study finds gut immune system struggling to clear lingering virus moneyweb.co.za
